صفحه 1:
(7۹4 GOO

صفحه 2:
DLE ۱/۹0 (۹۹/2۹/2 ۹2 710 ۳

صفحه 3:
ا ا 040 4 لك كك © ا 0 و ۹ ‎cara nn ees Dec eared‏ ا ل ا 0

صفحه 4:
- ۳ ۷ ech eta tczNSLcaic 0 ans Ae NSE ea ‏مس مس سم‎ EAST ‎(nex hie oases nmcrA ea eeeAclis real eat}‏ با 5 ‏ل ۱۹ ۴ ‎WO inca ccd

صفحه 5:
‎Ea Tih TA Mi eS a Nate lend dB Nd tk a‏ د ‏0 ۵ را( (130201) 00502050003000 ‎* PREGOCOC Sy) COG/ POR 0 / ee eee ‎Olood vole [Oa retention /(Edeua ‏ام‎ ‎0000030006000“ CONS ‏ری ایا‎ ‏بان

صفحه 6:
۹ | ‏که‎ ۱ alk en ‏ا‎ (ONY (GY GROG Opa] a tology: NCS ‏رک‎ ran] (yee Nee (per DOep/@Ovp

صفحه 7:
۹ ٩ ‏اد‎ الل ا 4 0 " Veracca AOD ‏ععددادطا‎ ‎Oe acct Dac ele AS Nese cd (PACA Cg aS IRS SATS‏ و ‎CaN aise‏ ل ‎Ta‏ ‏نا سوب 20 ۱ ‎۲ State (ea) ‏ا [ ۲ ‏رک ‏( مك ا" ‎

صفحه 8:
CSN eI CAC EA ASCII ONSET ‏رل دی ور‎ ۶ ‏رن(‎ ۱ ۱ eis cam Operas) Op)iCZ (AN ¢p\@o 0 NN eS cd 2 @ro/ Or 0 2

صفحه 9:
(۹۹۹ 0 2 cl BCI PAC EL ANSI BOSC ASDA SRS Uppured ۳1 0 cr uicasraciiea #۵

صفحه 10:
ا 20۱ ور و71۱۳ ۱ ل 1۳۹ یریش 4 ل 0 01 5 0 4 ‏رو‎ Uses اس و 3 ‎Crd Oca‏ الم ‎0 1 =pToO/ PCH ‎0 CANO) ‎۰ ‏رح ‏چست سح ‎ORE‏

صفحه 11:
۹/۹۹/2۹۹4 MRP ID PREGOOOCY

صفحه 12:
(۹۹۱ 10) PRECOOOCY bol irra cacy ccc Ud . OW eee it and 0 OD.G ۴

صفحه 13:
OP110 PREGOOOOY " Prevdeurr (C-10% ) ) كسك سرس ۱۳ دور رو() = کت ل سم سره اک مت اک ۹ با 0 و( 5 ‎Gevoucd trivester‏ >== ره ‎5 ‏مک‎ ta rod) preceremy ٩ ‏د الك ا در ز()‎

صفحه 14:
ا 4 ® Previous history oP OM ON ca ik (ra cecan ae ed ۱ ‏را‎ cifasiez BLP *OO 0 ‏رز‎ eISSN cd

صفحه 15:
PRE-OMGMOG REOSL ‏لا»‎ ۳ ۱۹7 ‏ا‎ PZ PL AS DANSE BA Ni CAS Ea ANSON EIS Ea a ae | mOsizicasl (Oza O cmc he LOO I erie mse iis ed ۱/2 ۱2 5 4225 ‏ار ۱۵۱۹۱۵۹۵۹ كك‎ / POM

صفحه 16:
‎rac eee eater, Pal ecrea|‏ با 0ه ‎0 ۵ ‏ره تراک ار ‎3 ‏ادوج‎ nO rahe aac aia ke) 2030202020200 102 (۸ ۶ bl Tea aca EAC a xr ean 62 2 Ee ee ee ene)

صفحه 17:
2۹۳۹07 (۹ (WO) Chou GO OTD 4

صفحه 18:
CO1IDEMNOE ‏لكا‎ ‎OOMOOD OIML PRE- 2 (۹ OM ei ۲ Occ hac] * Ors (Weer exe oe DOr (n eel (Dyerrrrime| (areas ‏رای مر زک با‎ 0 aia east

صفحه 19:
© ‏ا ال ل‎ PASE ECD Ie ٩ ‏ارحص ار‎ 01 ‏رصح‎ cecn Decca) bel (oc Vance cies eR aces heer ee ane eas cas eal ac a at 2 0 ا ۳ پم و 0” ‏ل‎ oe eae 00 cat 0” pc eee Vics ‏کر‎ cas Leche ance cczca ‏دا‎ el es her cameras ‏ل‎ ACD)

صفحه 20:
۹۱۱۹۱ 500502030005000 oat coe eC Co hace anata | ‏دوجم خان امجبووساورجل عونا‎ : CCN (NC er BR ULC ee Oe a 0 4 (hae ay Ore ee ee ee ace a ۱ AN) ‏.بطم 0۵2۵۵ :۵ 0ك‎ 0۵۵2۵0 ۱ ead orga darage | Bro: BP<IPO/OO Cae ad AKO, ete een ee nC ۵0:00 لك

صفحه 21:

IN THE NAME OF GOD THE NORMAL AND DISEASED KIDNEY IN PREGNANCY PREGNANCY-INDUCED CHANGES IN ANATOMY  Length of kidney  Length of PT  Kidney volume  Capacity of the dilated renal collecting system  Pregnancy     inhibits ureteral peristalsis distention of ureter mechanical obstruction ureteral hypomotility Pregnancy ureteral distention Pregnancy smooth muscle relaxation VUR Etiology of the UT dilatation in pregnancy Clinical relevance CARDIOVASCULAR AND RENAL PHYSIOLOGY IN PREGNANCY  PREGNANCY COP/ PVR / RVR /  PREGNANCY RBF / RPF/ RVR BP Blood volume /Na retention /Edema  Clinical relevance R-A-A-S in pregnancy  Pregnancy R/ A/ PRA /Pro-R  Etiology : PGI2 Renin secretion Resistance to A2 Nepi/Avp Renal tubular function         GTB in pregnancy (PT/DT) Normal Na balance Normal water balance(ability to produce a maximally concentrated&maximally dilute urine 24h urine volume Plasma Na level(5 meq/l ) Plasma osmolality (10 mosmol/kg h2o) Osmotic threshold for AVP release (285 276) Osmotic thirst threshold (290 280 ) Evaluation of renal function in pregnancy  Examination of the urine :Pro/Alb/RBC  Creatinin clearance  Pro/ Cr  Cockroft-Gault formula RENAL BIOPSY  Sudden deterioration of renal function with no apparent cause  Symptomatic NS Theclinical spectrum&management of renal disorders in gestation  Pregnancy associated ARF pattern  Pre-renal      Bimodal Hyperemesis gravidarum Bleeding Post-renal Stone/ Tumor Renal ATN/ ACN Preeclampsia ATN HELLP SYN. ARF MANAGEMENT OF ARF IN PREGNANCY NEPHROLITHIASIS IN PREGNANCY  Frequency  Type of stone  DX  Treatment UTI IN PREGNANCY  Prevalence (2-10% )  Asymptomatic bacteriuria (6-7%)  Acute pyelonephritis (20- 30%)  Screening (16 W )  Baceriuria post delivery (17%)  Symptomatic infection(3%)   Cystitis (./3 -1/3 %) Pyelonephritis (1-3%) Secound trimester 10% in early pregnancy  Management of UTI in pregnancy RF for bacteriuria in pregnancy  Previous history of UTI  Multiparity  Presence of HbS  Lower socioeconomic status  Sexual activity  DM  Advanced maternal age PRE-EXISTING RENAL DISEASE  Normotensive women with intact or only mildly decrease and stable renal function(Cr<1/4mg/dl )  Live birth :95%  Frequeency of preeclampsia /HTN /Proteinuria in late pregnancy  Exception :LN/ MPGN /SS / PAN  Moderate impairment :1/5mg/dl<Cr<3mg/dl Live birth :90% Fetal GR &Preterm delivery>50% Renal function deterioration >1/3  PREGNANCY IS NOT ADVISABLE  Severe impairement : Cr >3mg/dl Incidence of IP hemorrhage /severe HTN SPECEFIC DISEASE  DM Chronic  CTD  Reflux GN nephropathy GUIDELINE ON MANAGING WOMAN WITH PREEXISTING RENAL DISEASE  Counseling  Cr<1/4mg/dl Normotensive:DBP=90mmhg  Follow up  Diuretic &NS  Pro- restriction Obstetrical management of women with underlying renal disease       Frequency of prenatal visit (every two weeks until the third trimester and then weekly ) Early detection &treatment of asymptomatic bacteriuria Serial monitoring (at least monthly ) of maternal renal function Close monitoring for the development of the preeclampsia Fetal surveillance with US&FHR monitoring to assess FG &well-being Treatment of maternal HTN HTN &PREGNANCY  Physiologic changes in BP during normal pregnancy  Hypertensive level of BP for development of preeclampsia : SBP>140 mmhg  Risk of HTN   DBP>90mmhg Fetal risk : IUGR / perinatal death / Preterm delivery Maternal risk : preeclampsia / proteinuria Treatment of HTN Acute HTN: DBP>100 mmhg DBP>90mmhg Chronic HTN with end organ damage : Goal: BP<140/90 Chronic HTN without end organ damage :Goal:SBP:140-150 DBP:90-100mmhg

62,000 تومان